Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.35 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.35 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10743825 | 0.61 | CYP19A1 (0.57) | TSHR | |
| SCHEMBL1053251 | 0.60 | P2RX3 (0.55) | — | |
| SCHEMBL9516529 | 0.57 | LMNA (0.57) | NPC1RAB9ASMN1; SMN2MEN1MAPT | |
| SCHEMBL1686571 | 0.57 | LMNA (0.57) | NPC1RAB9ASMN1; SMN2MEN1MAPT | |
| SCHEMBL668905 | 0.57 | SLC6A4 (0.47) | KDM1A | |
| SCHEMBL11630110 | 0.57 | KCNH3 (0.59) | NPC1RAB9ASMN1; SMN2MEN1MAPT | |
| SCHEMBL18003438 | 0.56 | MAPT (0.59) | NPC1RAB9ASMN1; SMN2MEN1MAPT | |
| SCHEMBL30405788 | 0.56 | CSNK2A1 (0.69) | NPC1RAB9ASMN1; SMN2MEN1MAPT | |
| SCHEMBL28707172 | 0.55 | KDM1A (0.76) | NPC1RAB9ASMN1; SMN2MEN1MAPT | |
| Hydrochloric Acid SCHEMBL1919156 | 0.55 | SLC6A4 (0.45) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9675596-B2 | 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer | BALTIC BIO AB (SE) | 2017-06-13 | — | — | US | claimed |
| US-20160128993-A1 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BALTICGRUPPEN BIO AB (SE) | 2016-05-12 | — | — | US | claimed |
| EP-2451794-B1 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BALTIC BIO AB (SE) | 2016-01-27 | — | — | EP | claimed |
| US-9162994-B2 | 1,2,4-thiazoloidin-3-one derivatives and their use in the treatment of cancer | BETAGENON AB (SE) | 2015-10-20 | — | — | US | claimed |
| US-20120183537-A1 | 1,2,4-THIAZOLOIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BETAGENON AB | 2012-07-19 | — | — | US | claimed |
| EP-2451794-A2 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BALTIC BIO AB (SE) | 2012-05-16 | — | — | EP | claimed |
| WO-2011004162-A2 | COMPOUNDS USEFUL AS MEDICAMENTS | BETAGENON AB (SE) | 2011-01-13 | — | — | WO | claimed |
| US-9675596-B2 | 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer | BALTIC BIO AB (SE) | 2017-06-13 | — | — | US | disclosed |
| US-9675596-B2 | 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer | BALTIC BIO AB (SE) | 2017-06-13 | — | — | US | disclosed |
| US-20160128993-A1 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BALTICGRUPPEN BIO AB (SE) | 2016-05-12 | — | — | US | disclosed |
| EP-2451794-B1 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BALTIC BIO AB (SE) | 2016-01-27 | — | — | EP | disclosed |
| US-9162994-B2 | 1,2,4-thiazoloidin-3-one derivatives and their use in the treatment of cancer | BETAGENON AB (SE) | 2015-10-20 | — | — | US | disclosed |
| US-20120183537-A1 | 1,2,4-THIAZOLOIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BETAGENON AB | 2012-07-19 | — | — | US | disclosed |
| EP-2451794-A2 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BALTIC BIO AB (SE) | 2012-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160128993-A1 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | HCCS, CCND3, MTNR1A | NPC1 3043/4885RAB9A 2210/4885SMN1; SMN2 2650/4885 |
| US-20120183537-A1 | 1,2,4-THIAZOLOIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | HCCS, CCND3, MTNR1A | NPC1 3107/4885RAB9A 1865/4885SMN1; SMN2 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.